初诊系统性红斑狼疮抗双链DNA抗体表达对治疗效果的影响  

Effect of anti-ds-DNA antibody expression on therapeutic effect of newly diagnosed systemic lupus erythematosus

作　　者：曹思曼 周毅[1] 朱丽花[1] 曾珊 CAO Siman;ZHOU Yi;ZHU Lihua;ZENG Shan(Department of Rheumatism and Immunity,the First Affiliated Hospital of Jinan University,Guangzhou,Guangdong 510630,China)

机构地区：[1]暨南大学附属第一医院风湿免疫科,广东广州510630

出　　处：《现代医药卫生》2023年第4期547-550,共4页Journal of Modern Medicine & Health

摘　　要：目的 分析初诊系统性红斑狼疮患者抗双链DNA抗体表达对治疗效果的影响。方法 选取2013年1月至2021年6月该院风湿免疫科收治的115例初诊系统性红斑狼疮患者作为研究对象,按照抗双链DNA抗体表达与否分为抗双链DNA抗体阴性组(n=37)和抗双链DNA抗体阳性组(n=78),2组均规律使用激素联合环磷酰胺治疗,比较2组患者治疗第1、2、3、6个月疾病活动度评分,对比2组患者达标治疗率。结果 抗双链DNA抗体阴性组患者治疗第1个月达标治疗率为78.4%,第2个月达标治疗率为89.2%,第3个月达标治疗率为89.2%,第6个月达标治疗率为86.5%;抗双链DNA抗体阳性组患者治疗第1个月达标治疗率为48.7%,第2个月达标治疗率为75.6%,第3个月达标治疗率为83.3%,第6个月达标治疗率为80.8%。2组患者治疗第1、2、3个月达标治疗率比较,差异均有统计学意义(P<0.05);2组患者治疗第6个月达标治疗率比较,差异无统计学意义(P>0.05)。结论 抗双链DNA抗体对患者早期治疗方案的调整、提高系统性红斑狼疮总的达标治疗率具有一定提示意义;并建议在系统性红斑狼疮最初治疗的3个月内对抗双链DNA抗体阳性者应做到更加全面地评估,并延长随访时间,在达标治疗前尽可能减少器官损害,甚至降低死亡风险。Objective To analyze the therapeutic effect of anti-ds-DNA antibody expression on the newly diagnosed systemic lupus erythematosus(SLE).Methods A total of 115 patients with newly diagnosed SLE were selected from the Department of Rheumatism and Immunity, the First Affiliated Hospital of Jinan University from January 2013 to June 2021.According to the expression of anti-ds-DNA antibody, they were divided into anti-ds-DNA negative group(n=37) and anti-ds-DNA positive group(n=78).Both groups were regularly treated with hormone combined with cyclophosphamide.Disease activity scores of the first, second, third and sixth months of treatment were compared between the two groups, and the standard treatment rates of the two groups were compared.Results The target treatment rate of anti-ds-DNA negative group was 78.4% in the first month, 89.2% in the second month, 89.2% in the third month, and 86.5% in the sixth month;the target treatment rate of anti-ds-DNA positive group was 48.7% in the first month, 75.6% in the second month, 83.3% in the third month, and 80.8% in the sixth month.There was significant difference in the target treatment rate between the two groups in the first, second, third months of treatment(P<0.05),but there was no significant difference in the target treatment rate between the two groups in the sixth month(P>0.05).Conclusion Anti-ds-DNA antibody has certain suggestive significance for the adjustment of early treatment plan and the improvement of the total target treatment rate of SLE.It is suggested that within three months of the initial treatment of SLE patients with positive anti-ds-DNA antibody should be evaluated more comprehensively, and the follow-up time should be extended to reduce the risk of organ damage and death as much as possible before reaching the target treatment.

关 键 词：系统性红斑狼疮 抗双链DNA抗体 初诊 达标治疗 

分 类 号：R593.2[医药卫生—内科学]